Houston, TX, January 11, 2006 --(PR.com
)-- Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announced the signing of three contracts with an aggregate value of $13.4 million. The contracts involve patient recruitment, site selection, project management, biostatistics, monitoring, and regulatory affairs in the therapeutic areas of pain, cardiovascular disease, and ophthalmology.
The trials involve over a thousand patients, the majority of which come from sites across Central and Eastern Europe. “Selecting sites outside the United States was the logical choice because the large numbers of treatment naïve patients, lower drop out rates, and lower site and investigator fees for our sponsors,” said Iain Gordon, POI’s Director of Global Business Development. “We have our own offices in these countries for monitoring studies and to assure protocol compliance while meeting ICH-GCPs guidelines.”
In 2005 Pharm-Olam experienced the largest year of growth in the history of the company. “Although 2005 was a record year for Pharm-Olam, we are even more excited about the future. Our expansion in the emerging markets of Southeast Asia, India, and Latin America for clinical trials offers a huge potential for continued growth,” said Iain. “Pharm-Olam’s proven ability to expand rapidly into new global markets is a testimony of our staff’s expertise and dedication.”
For further information about Pharm-Olam please contact Iain Gordon at email@example.com.
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.